WHO Confirms Xaranetide as INN for ARG-007
Filed with ASX · · 1 page · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- IND Application Advanced With Successful Completion of Assay
- Clinical Advisory Committee Established to Advance Phase 2b
- Presentations at European Stroke Organisation Conference
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Half Yearly Report and Accounts
Later from Argenica Therapeutics
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- ARG007 Shows Significant Neuroprotection in Concussion Study
- Notification of cessation of securities - AGN
- Appendix 4G & Corporate Governance Statement
- Appendix 4E & Annual Report to 30 June 2026
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics